Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
Recruiting now NCT06508567
Run by University Health Network, Toronto · for 18 and older · Men
What this study is about
This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.
Who can join (things the study team will check)
✅ You may be able to join if…
- Patients who received previous RT to the prostate bed +/- pelvic nodal regions
- Prostate-bed recurrence identified by biopsy and/or MRI and/or PSMA-PET scan
- At least two continuous PSA elevations post RT and PSA above 0.2 ng/dl
- With or without ADT PSA doubling time from nadir greater than 6 months
- ECOG 0-2
- Age greater than 18 years
🚫 You may not be able to join if…
- Radiological (e.g. PSMA PET, CT, MRI or bone scan) evidence of or distant metastases
- History of ≥G3 gastrointestinal (GI) and genitourinary (GU) toxicities following RT
- Any contraindications to MR and/or brachytherapy
Where this trial is running
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Who to contact
Peter Chung, MD · 416-946-4501 · peter.chung@uhn.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06508567.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.